Film Coated Tablets
Composition and excipients:
The Actives
Each film coated tablet contains:
Micronized purified flavonoic fraction 500 mg corresponding to: Diosmin: 90 % = 450 mg & flavonoids expressed as hesperidin: 10% = 50 mg .
Core : microcrystalline cellulose, magnesium stearate, Sodium Lauryl Sulphate,Sodium starch glycolate, talc , gelatin. 
Dye, FD & C Yellow No. 6, Al lake , Macrogol 6000 , Talc , Titanium dioxide, polyvinyl alcohol .
Mode of Action :
This product is a phlebotonic drug and a vascular-protecting agent. It reinforces venous tone by prolonging the activity of parietal noradrenaline. This product normalizes capillary permeability and strengthens capillary resistance. It improves lymphatic drainage by increasing lymph flow and lymph oncotic pressure. This product significantly improves disabling symptoms of venous insufficiency which affect every day active life: Heavy legs, pain, heat sensation, edema, functional impairment and nocturnal cramps. This product is highly effective in the treatment of chronic hemorrhoidal disease. It significantly improves subjective symptoms and objective signs , e.g. anal discomfort, pain, redness, anal discharge, proctitis, tenesmus, pruritus, erythema and bleeding. This product also significantly reduces the frequency, severity and duration of acute hemorrhoidal attacks and bleeding by chronic treatment. 

• Treatment of the symptoms and signs of organic and idiopathic chronic venous disease of the lower limbs ,e.g. heavy legs, pain, heat sensation, edema, functional impairment and nocturnal cramps .
• Treatment of the symptoms of acute hemorrhoidal attacks and chronic hemorrhoidal disease.

Hypersensitivity to the active substance or to any of the excipients.

Adverse Reactions:
Common: Diarrhea, dyspepsia, nausea, vomiting.
Uncommon: Colitis.

• The administration of this product for the symptomatic treatment of acute hemorrhoids does not preclude treatment for other anal conditions.
• If symptoms do not subside promptly, a proctological examination should be performed and the treatment should be reviewed.

Pregnancy & lactation:
Experimental studies have not shown any teratogenic effect in animals. In human beings, no harmful effect has so far been reported.
In the absence of data concerning the diffusion into breast milk, breastfeeding is not recommended during treatment. 

Dosage and administration:
Chronic Venous Disease: 2 tablets daily with meals.
Chronic Hemorrhoidal Disease: 2 tablets daily with meals.
Acute Hemorrhoidal Attack: 6 tablets daily (in 2 divided doses) for 4 days, then 4 tablets daily (in 2 divided doses) for 3 days, 2 tablets thereafter.

Storage conditions: Store at 25oC
Presentation: Pack of 30 F.C.Tablets.